Aethlon Medical: chief medical officer Steven P LaRosa received 42,000 shares

What happened

• Steven P LaRosa, chief medical officer, received a grant of 42,000 restricted stock units (RSUs) on Oct 8, 2026. The reported acquisition price was $0.00 per RSU, total $0.

Key details

• Transaction date and code: Oct 8, 2026; code A (award/grant); 42,000 RSUs @ $0.00, total $0.
• Shares owned after the transaction: not reported in the filing.
• Footnote: the filing says the RSUs were granted under the Issuer's 2020 Equity Incentive Plan. Each RSU is a contingent right to receive one share on settlement. The RSUs vest over the 1-year period following Oct 8, 2026, subject to continued service, and will become fully vested upon closing of the Issuer's proposed merger with North Immunology, Inc.
• Filing date: Oct 15, 2026; the filing does not indicate a late-filing code.

Why it may matter

• This was an award of RSUs, not a public market purchase or sale.
• Vesting is time- and service-based (1-year schedule) and includes a provision that accelerates vesting upon closing of the proposed merger with North Immunology, Inc.
• A filing does not show why the insider traded or why the company acted.